(Bloomberg) Novo Nordisk A/S shares fell on Wednesday in the first trading session following a split aimed at increasing the liquidity of the Danish drugmaker’s soaring stock.Most Read from BloombergLuxury Cruise Ship Full of Australians Stuck in Greenland ArcticiPhone Pro’s Titanium Finish Stands Out in First Look at DeviceChina Flags ‘Security Incidents’ With Apple’s iPhonesApple’s iPhone 15 Debut Includes Higher Price on Top ModelAT&T, T-Mobile Offer Free iPhone 15 in Lure for New Subscrib
In his latest research note, analyst Michael Leuchten confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price is unchanged and still at GBX 13000.